Pacer Advisors
BEAM icon

Pacer Advisors’s Beam Therapeutics BEAM Stock Holding History

Pacer Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-940
Closed -$22K – 2579
2024
Q2 		$22K Sell
940
-194
-17% -$4.76K ﹤0.01% 3408
2024
Q1 		$37.5K Buy
+1,134
New +$35.3K ﹤0.01% 3287
2021
Q2 		– Sell
-791
Closed -$63K – 1426
2021
Q1 		$63K Sell
791
-742
-48% -$70.6K ﹤0.01% 1409
2020
Q4 		$125K Buy
+1,533
New +$75.4K ﹤0.01% 1328

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Pacer Advisors's BEAM Position: Q3 2024 in Review

Pacer Advisors sold out of Beam Therapeutics (BEAM) in Q3 2024, closing a stake of 940 shares — an estimated $22K sold.

Pacer Advisors first reported a position in BEAM in Q4 2020 and held it in 4 quarters. The position peaked at $125K in Q4 2020. 221 funds tracked by Wall St. Rank hold BEAM as of Q3 2024.

  • Pacer Advisors reported no remaining Beam Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 940 Beam Therapeutics shares in Q3 2024, an estimated $22K.
  • Pacer Advisors first reported a position in Beam Therapeutics in Q4 2020 and held it in 4 quarters.
  • Pacer Advisors's Beam Therapeutics position peaked at $125K in Q4 2020.
  • 221 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.